We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

236 hedge funds and large institutions have $1.23B invested in BioCryst Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 99 increasing their positions, 57 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

280% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $4.82M

74% more repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 57

1.78% more ownership

Funds ownership: 90.36% → 92.14% (+1.8%)

2% less funds holding

Funds holding: 241 → 236 (-5)

13% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 30

14% less capital invested

Capital invested by funds: $1.42B → $1.23B (-$196M)

25% less funds holding in top 10

Funds holding in top 10: 8 → 6 (-2)

Holders
236
Holders Change
-5
Holders Change %
-2.07%
% of All Funds
3.71%
Holding in Top 10
6
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-25%
% of All Funds
0.09%
New
26
Increased
99
Reduced
57
Closed
30
Calls
$18.3M
Puts
$4.82M
Net Calls
+$13.5M
Net Calls Change
-$2.37M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$31.7M
2
RHJA
Rice Hall James & Associates
California
+$15M
3
KCM
Kynam Capital Management
New Jersey
+$14.8M
4
ACA
Avoro Capital Advisors
New York
+$13.1M
5
PM
Prosight Management
Texas
+$11.4M

Top Sellers

1
Artisan Partners
Artisan Partners
Wisconsin
-$23.7M
2
Bank of America
Bank of America
North Carolina
-$18.1M
3
PHS
PFM Health Sciences
California
-$18M
4
EP
Eversept Partners
New York
-$17.2M
5
DM
Deerfield Management
New York
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
JF
101
Jump Financial
Illinois
$605K -$1.83M -227,665 -73%
DA
102
Doliver Advisors
Texas
$570K – – –
VRS
103
Virginia Retirement Systems
Virginia
$567K +$521K +64,900 +413%
Janus Henderson Group
104
Janus Henderson Group
United Kingdom
$566K -$690 -86 -0.1%
AIM
105
Aigen Investment Management
New York
$551K +$287K +35,772 +84%
Manulife (Manufacturers Life Insurance)
106
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$542K +$20K +2,497 +3%
Tudor Investment Corp
107
Tudor Investment Corp
Connecticut
$540K +$615K +76,662 New
DekaBank Deutsche Girozentrale
108
DekaBank Deutsche Girozentrale
Germany
$512K – – –
GC
109
Grimes & Company
Massachusetts
$512K +$2.81K +350 +0.5%
GCP
110
GSA Capital Partners
United Kingdom
$504K -$660K -82,186 -53%
HS
111
HighVista Strategies
Massachusetts
$484K +$552K +68,725 New
BRA
112
Bender Robert & Associates
California
$483K – – –
PCS
113
Personal CFO Solutions
New Jersey
$470K -$8.03K -1,000 -1%
JFG
114
Jefferies Financial Group
New York
$458K +$522K +65,000 New
Hudson Bay Capital Management
115
Hudson Bay Capital Management
Connecticut
$455K +$178K +22,200 +52%
New York State Common Retirement Fund
116
New York State Common Retirement Fund
New York
$439K -$1.16M -144,695 -70%
NFC
117
Northeast Financial Consultants
Connecticut
$427K – – –
State Board of Administration of Florida Retirement System
118
State Board of Administration of Florida Retirement System
Florida
$396K – – –
ASRS
119
Arizona State Retirement System
Arizona
$373K -$8.71K -1,085 -2%
EFM
120
E Fund Management
China
$369K +$46.8K +5,838 +13%
Mackenzie Financial
121
Mackenzie Financial
Ontario, Canada
$367K -$54.6K -6,798 -12%
Teacher Retirement System of Texas
122
Teacher Retirement System of Texas
Texas
$360K -$50.6K -6,309 -11%
FSA
123
Franklin Street Advisors
North Carolina
$352K – – –
SIG
124
Stonegate Investment Group
Alabama
$345K – – –
Russell Investments Group
125
Russell Investments Group
United Kingdom
$343K -$991K -123,485 -72%
3 4
5
6 7

BCRX Hedge Fund Activity: Q2 2023 in Review

236 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q2 2023, worth a combined $1.23B — down 14% from $1.42B a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of BCRX and 26 opened new positions — a net loss of 4 holders — while 57 trimmed existing stakes and 99 added.

The largest buyer was Point72 Asset Management, adding an estimated $31.7M. The largest seller was Artisan Partners, exiting entirely with an estimated $23.7M sold.

  • 236 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q2 2023, down from 241 in Q1 2023.
  • Funds reported $1.23B of BioCryst Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q2 2023 and 30 closed out, a net change of -4 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q2 2023 was Point72 Asset Management, an estimated $31.7M added.
  • The largest BioCryst Pharmaceuticals seller in Q2 2023 was Artisan Partners, an estimated $23.7M sold.

Based on aggregated 13F filings for Q2 2023.